Skip to main content
eScholarship
Open Access Publications from the University of California

Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.

  • Author(s): Grant, Igor
  • Franklin, Donald R
  • Deutsch, Reena
  • Woods, Steven P
  • Vaida, Florin
  • Ellis, Ronald J
  • Letendre, Scott L
  • Marcotte, Thomas D
  • Atkinson, JH
  • Collier, Ann C
  • Marra, Christina M
  • Clifford, David B
  • Gelman, Benjamin B
  • McArthur, Justin C
  • Morgello, Susan
  • Simpson, David M
  • McCutchan, John A
  • Abramson, Ian
  • Gamst, Anthony
  • Fennema-Notestine, Christine
  • Smith, Davey M
  • Heaton, Robert K
  • CHARTER Group
  • et al.

Published Web Location

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118496/
No data is associated with this publication.
Creative Commons Attribution-NoDerivatives 4.0 International Public License
Abstract

OBJECTIVE:While HIV-associated neurocognitive disorders (HAND) remain prevalent despite combination antiretroviral therapy (CART), the clinical relevance of asymptomatic neurocognitive impairment (ANI), the most common HAND diagnosis, remains unclear. We investigated whether HIV-infected persons with ANI were more likely than those who were neurocognitively normal (NCN) to experience a decline in everyday functioning (symptomatic decline). METHODS:A total of 347 human participants from the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort were NCN (n = 226) or had ANI (n = 121) at baseline. Neurocognitive assessments occurred approximately every 6 months, with median (interquartile range) follow-up of 45.2 (28.7-63.7) months. Symptomatic decline was based on self-report (SR) or objective, performance-based (PB) problems in everyday functioning. Proportional hazards modeling was used to generate risk ratios for progression to symptomatic HAND after adjusting for baseline and time-dependent covariates, including CD4+ T-lymphocyte count (CD4), virologic suppression, CART, and mood. RESULTS:The ANI group had a shorter time to symptomatic HAND than the NCN after adjusting for baseline predictors: adjusted risk ratios for symptomatic HAND were 2.0 (confidence interval [CI] 1.1-3.6; p = 0.02) for SR, 5.8 (CI 3.2-10.7; p < 0.0001) for PB, and 3.2 (CI 2.0-5.0; p < 0.0001) for either SR or PB. Current CD4 and depression were significant time-dependent covariates, but antiretroviral regimen, virologic suppression, and substance abuse or dependence were not. CONCLUSIONS:This longitudinal study demonstrates that ANI conveys a 2-fold to 6-fold increase in risk for earlier development of symptomatic HAND, supporting the prognostic value of the ANI diagnosis in clinical settings. Identifying those at highest risk for symptomatic decline may offer an opportunity to modify treatment to delay progression.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item